Abstract Oncotype DX Breast Recurrence Score® is a 21-gene prognostic and predictive
assay indicated for use in patients with hormone receptor-positive, human epidermal growth …

Background OncotypeDX® recurrence score (RS) aids therapeutic decision-making in
oestrogen-receptor-positive (ER+) breast cancer. Radiomics is an evolving field that aims to …

Clinicopathological prognostic features have limited value to identify with precision newly
diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer …

Abstract Purpose In Italy, Lombardy was the first region to reimburse multigene assays
(MGAs) for patients otherwise candidates for chemotherapy. This is a real-world experience …

CanAssist Breast (CAB) has thus far been validated on a retrospective cohort of 1123
patients who are mostly Indians. Distant metastasis–free survival (DMFS) of more than 95 …

Background Decision impact studies have become increasingly prevalent in cancer
prognostic research in recent years. These studies aim to evaluate the impact of a genomic …

Background The 21-gene assay (the Oncotype DX Breast Recurrence Score® test) is a
validated multigene assay which produces the Recurrence Score® result (RS) to inform …

Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype
DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant …

Introduction Chemotherapy (CT) is commonly used as an adjuvant treatment for women with
early breast cancer (BC). However, not all patients benefit from CT, while all are exposed to …

Background Data published in 2015 showed that patients with early breast cancer (EBC)
and a low-risk (LR) Recurrence Score®(RS) result by the 21-gene Oncotype DX® assay …